$14.82
0.68% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US19240Q2012
Symbol
COGT

Cogent Biosciences Inc Stock price

$14.82
-0.62 4.02% 1M
+10.10 213.98% 6M
+7.02 90.00% YTD
+4.77 47.46% 1Y
+3.13 26.78% 3Y
+4.77 47.46% 5Y
-29.62 66.65% 10Y
-29.62 66.65% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
+0.10 0.68%
ISIN
US19240Q2012
Symbol
COGT
Industry

Key metrics

Basic
Market capitalization
$2.1b
Enterprise Value
$1.9b
Net debt
positive
Cash
$237.9m
Shares outstanding
113.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
13.4
Financial Health
Equity Ratio
78.2%
Return on Equity
-78.4%
ROCE
-138.5%
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-297.1m | $-208.1m
EBIT
$-299.7m | $-310.4m
Net Income
$-204.5m | $-258.2m
Free Cash Flow
$-234.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-23.1% | 23.9%
EBIT
-22.9% | -12.5%
Net Income
4.8% | -28.4%
Free Cash Flow
-32.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.8
FCF per Share
$-2.1
Short interest
13.2%
Employees
205
Rev per Employee
$0.0
Show more

Is Cogent Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Cogent Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Cogent Biosciences Inc forecast:

14x Buy
74%
5x Hold
26%

Analyst Opinions

19 Analysts have issued a Cogent Biosciences Inc forecast:

Buy
74%
Hold
26%

Financial data from Cogent Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 49 49
26% 26%
-
- Research and Development Expense 251 251
22% 22%
-
-297 -297
23% 23%
-
- Depreciation and Amortization 2.54 2.54
6% 6%
-
EBIT (Operating Income) EBIT -300 -300
23% 23%
-
Net Profit -204 -204
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cogent Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cogent Biosciences Inc Stock News

Neutral
GlobeNewsWire
5 days ago
Phase 3 PEAK results in 2 nd -line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December
Neutral
GlobeNewsWire
5 days ago
SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent's newest preclinical program; on-track for IND in 2026 WALTHAM, Mass. and BOULDER, Colo.
Neutral
GlobeNewsWire
15 days ago
WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced updated preclinical data from the company's potent and selective pan KRAS(ON) inhibitor in a poster presentation at the 2025 AACR-NCI-EORTC International Conference on Mo...
More Cogent Biosciences Inc News

Company Profile

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Robbins
Employees 205
Founded 2014
Website www.cogentbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today